Raymond James & Associates, a prominent investment management company, has recently increased its stake in Haleon plc, a major player in the financial industry. According to a disclosure filed with the Securities and Exchange Commission (SEC), Raymond James & Associates acquired an additional 95,535 shares of Haleon stock during the first quarter of this year. This move raised their overall ownership to 2,138,035 shares. At the end of the most recent quarter, the total value of Raymond James & Associates’ holdings in Haleon amounted to a substantial $17,404,000.
This significant increase in stake demonstrates Raymond James & Associates’ confidence and belief in the potential growth and success of Haleon plc. As an established hedge fund with a strong track record, their decision to invest further indicates a positive outlook for Haleon’s future performance.
For those interested in gaining further insights into Haleon’s position amongst other hedge funds active in the market, HoldingsChannel.com provides up-to-date information on 13F filings and insider trades relating specifically to Haleon plc (NYSE:HLN). These details can aid investors in understanding how various hedge funds view and approach their investments in Haleon.
As for the current state of HLN stock itself, it opened at $8.38 on Monday. Over the past fifty days, its moving average has hovered around $8.47, indicating stability within that timeframe. Similarly, looking at its 200-day moving average value of $8.22 reveals consistency within a longer period.
Haleon plc’s share price has witnessed fluctuation over the past twelve months, showing both lows and highs. The lowest recorded point was $5.59 while it reached its peak at $9.05 during this period. This price volatility showcases the dynamic nature of the market and highlights potential opportunities for investors seeking fluctuations in stock values.
Analyzing key financial ratios can provide further insight into Haleon’s performance. The company boasts a quick ratio of 0.62, indicating its ability to meet short-term obligations with available liquid assets. Additionally, a current ratio of 0.93 suggests that Haleon has an adequate amount of current assets to cover its liabilities. These ratios demonstrate the company’s financial stability and the prudence with which it manages its resources.
It is worth noting that Haleon currently maintains a debt-to-equity ratio of 0.61, indicating a conservative stance in managing its capital structure. A lower ratio implies that the company relies less on borrowed funds and maintains stronger equity levels.
As of now, Haleon plc remains focused on delivering value to its shareholders while navigating the ever-changing financial landscape. With Raymond James & Associates increasing their stake in the company, it further solidifies confidence in their growth prospects.
Investors intrigued by Haleon plc can keep abreast of the latest developments by monitoring relevant filings and insider trades on HoldingsChannel.com. As the market evolves, it is crucial for investors to stay informed and maintain an understanding of how various hedge funds view and respond to industry dynamics.
Disclaimer: The information provided in this article is based on public disclosures filed with the SEC and other reliable sources as of July 3, 2023. It is important for individuals to conduct additional research or consult with a financial advisor before making any investment decisions based on this information alone.
[bs_slider_forecast ticker=”HLN”]
Institutional Investors Flock to Haleon plc and Analysts Differ on Stock Performance
July 3, 2023 – Institutional investors have been showing significant interest in Haleon plc (NYSE:HLN), a global consumer healthcare company known for its wide range of products. Recent filings indicate that several hedge funds and institutional investors have both bought and sold shares of the stock.
Clearbridge Investments LLC, a prominent investment firm, increased its stake in Haleon by an impressive 31.0% in the fourth quarter. The firm now owns a staggering 25,704,881 shares of the company’s stock, with an estimated value of $205,639,000. This increase was a result of Clearbridge Investments LLC purchasing an additional 6,089,500 shares during the last quarter.
Price T Rowe Associates Inc. MD also joined the list of institutional investors interested in Haleon when they purchased a new stake in the company during the third quarter. The stake was valued at approximately $87,417,000.
Bain Capital Public Equity Management II LLC is another notable investor that acquired a new stake in Haleon during the third quarter, valuing it at approximately $59,351,000.
JTC Employer Solutions Trustee Ltd demonstrated confidence in Haleon by increasing its stake by 0.7%, resulting in ownership of 8,762,862 shares valued at $70,146,000.
State Street Corp completed this list of institutional investors by purchasing a new position in Haleon during the third quarter for approximately $50,724,000. With these investments combined, institutional investors now own roughly 6.67% of Haleon’s outstanding stock.
Apart from institutional investments making headlines for Haleon plc on July 3rd this year but equity analysts have also shared their reports on this consumer healthcare giant recently and their opinions seem to differ slightly. Stifel Nicolaus released their research note on May 24th stating that they considered “hold” rating appropriate for the company. On the other hand, Argus downgraded Haleon from a “hold” rating to a “buy” rating in another research note on April 6th. An additional report from Sanford C. Bernstein was released on April 4th, where they expressed an “outperform” rating for Haleon’s stock. Overall, two analysts have given the stock a sell rating, four have suggested holding it, and eight analysts have highly recommended buying shares of Haleon plc. Currently, based on data from Bloomberg, the average rating given to Haleon is “Hold,” with an average target price of $364.00.
Investors curious about other hedge funds that hold shares of HLN can find more information and recent filings at HoldingsChannel.com. They can also access data related to insider trades and monitor trends in the company’s ownership.
The latest earnings results for Haleon were released on May 3rd this year. Unfortunately, the company reported lower-than-expected earnings per share (EPS) of $0.10 for the quarter, falling short of analysts’ consensus estimate by ($0.03). Despite this setback, Haleon managed to generate revenue totaling $3.63 billion during the same period.
Looking ahead, sell-side analysts anticipate that Haleon plc will post an EPS of $0.46 for the current fiscal year.
Haleon plc operates on a global scale and is primarily engaged in researching, developing, manufacturing, and selling various consumer healthcare products across different continents such as North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. The company offers a wide variety of products including oral health solutions, pain relief medications, respiratory health treatments,
digestive health aids,
and assorted vitamins,
minerals,
and supplements.
As institutional investors continue to demonstrate interest in Haleon plc and equity analysts express diverse opinions regarding its stock performance,
the future prospects for this consumer healthcare giant remain the subject of ongoing speculation within financial circles. As Haleon strives to maintain its position in the global market,
the company’s ability to adapt to evolving consumer demands and deliver innovative healthcare solutions will be critical for its long-term success.